Glenmark Launches Biosimilar Antidiabetic Drug in India
January 3, 2024 10:51
Glenmark Pharmaceuticals launches Lirafit, a biosimilar antidiabetic drug, in India at a lower cost than Liraglutide, providing effective treatment for type 2 diabetes mellitus.